Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells.

Literature DB >> 21659544

Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells.

Alejo A Morales¹, Metin Kurtoglu, Shannon M Matulis, Jiangxia Liu, David Siefker, Delia M Gutman, Jonathan L Kaufman, Kelvin P Lee, Sagar Lonial, Lawrence H Boise.

Abstract

Dependence on Bcl-2 proteins is a common feature of cancer cells and provides a therapeutic opportunity. ABT-737 is an antagonist of antiapoptotic Bcl-2 proteins and therefore is a good predictor of Bcl-x(L)/Bcl-2 dependence. Surprisingly, analysis of Mcl-1-dependent multiple myeloma cell lines revealed codependence on Bcl-2/Bcl-x(L) in half the cells tested. Codependence is not predicted by the expression level of antiapoptotic proteins, rather through interactions with Bim. Consistent with these findings, acquired resistance to ABT-737 results in loss of codependence through redistribution of Bim to Mcl-1. Overall, these results suggest that complex interactions, and not simply expression patterns of Bcl-2 proteins, need to be investigated to understand Bcl-2 dependence and how to better use agents, such as ABT-737.

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 2011 PMID： 21659544 PMCID： PMC3152498 DOI： 10.1182/blood-2011-01-327197

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

48 in total

1. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.

Authors: Shuang Chen; Yun Dai; Hisashi Harada; Paul Dent; Steven Grant
Journal: Cancer Res Date: 2007-01-15 Impact factor: 12.701

2. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.

Authors: Marina Konopleva; Rooha Contractor; Twee Tsao; Ismael Samudio; Peter P Ruvolo; Shinichi Kitada; Xingming Deng; Dayong Zhai; Yue-Xi Shi; Thomas Sneed; Monique Verhaegen; Maria Soengas; Vivian R Ruvolo; Teresa McQueen; Wendy D Schober; Julie C Watt; Tilahun Jiffar; Xiaoyang Ling; Frank C Marini; David Harris; Martin Dietrich; Zeev Estrov; James McCubrey; W Stratford May; John C Reed; Michael Andreeff
Journal: Cancer Cell Date: 2006-11 Impact factor: 31.743

3. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics.

Authors: Anthony Letai; Michael C Bassik; Loren D Walensky; Mia D Sorcinelli; Solly Weiler; Stanley J Korsmeyer
Journal: Cancer Cell Date: 2002-09 Impact factor: 31.743

4. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.

Authors: Victoria Del Gaizo Moore; Jennifer R Brown; Michael Certo; Tara M Love; Carl D Novina; Anthony Letai
Journal: J Clin Invest Date: 2007-01 Impact factor: 14.808

5. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak.

Authors: Simon N Willis; Jamie I Fletcher; Thomas Kaufmann; Mark F van Delft; Lin Chen; Peter E Czabotar; Helen Ierino; Erinna F Lee; W Douglas Fairlie; Philippe Bouillet; Andreas Strasser; Ruth M Kluck; Jerry M Adams; David C S Huang
Journal: Science Date: 2007-02-09 Impact factor: 47.728

6. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737.

Authors: Paula Hauck; Bo H Chao; Julie Litz; Geoffrey W Krystal
Journal: Mol Cancer Ther Date: 2009-04 Impact factor: 6.261

7. Multisite phosphorylation regulates Bim stability and apoptotic activity.

Authors: Anette Hübner; Tamera Barrett; Richard A Flavell; Roger J Davis
Journal: Mol Cell Date: 2008-05-23 Impact factor: 17.970

8. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL.

Authors: L H Boise; A J Minn; P J Noel; C H June; M A Accavitti; T Lindsten; C B Thompson
Journal: Immunity Date: 1995-07 Impact factor: 31.745

9. Activation of the JNK pathway promotes phosphorylation and degradation of BimEL--a novel mechanism of chemoresistance in T-cell acute lymphoblastic leukemia.

Authors: Kam Tong Leung; Karen Kwai-Har Li; Samuel Sai-Ming Sun; Paul Kay Sheung Chan; Vincent Eng-Choon Ooi; Lawrence Chi-Ming Chiu
Journal: Carcinogenesis Date: 2008-01-03 Impact factor: 4.944

10. BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists.

Authors: K C Goldsmith; B J Lestini; M Gross; L Ip; A Bhumbla; X Zhang; H Zhao; X Liu; M D Hogarty
Journal: Cell Death Differ Date: 2009-11-06 Impact factor: 15.828

75 in total

1. Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome.

Authors: Rodger E Tiedemann; Yuan Xao Zhu; Jessica Schmidt; Chang Xin Shi; Chris Sereduk; Hongwei Yin; Spyro Mousses; A Keith Stewart
Journal: Cancer Res Date: 2011-12-06 Impact factor: 12.701

2. The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.

Authors: Manali S Phadke; Patrizia Sini; Keiran S M Smalley
Journal: Mol Cancer Ther Date: 2015-04-14 Impact factor: 6.261

3. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.

Authors: M Konopleva; M Milella; P Ruvolo; J C Watts; M R Ricciardi; B Korchin; T McQueen; W Bornmann; T Tsao; P Bergamo; D H Mak; W Chen; J McCubrey; A Tafuri; M Andreeff
Journal: Leukemia Date: 2011-11-08 Impact factor: 11.528

4. Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma.

Authors: Vikas A Gupta; Shannon M Matulis; Jason E Conage-Pough; Ajay K Nooka; Jonathan L Kaufman; Sagar Lonial; Lawrence H Boise
Journal: Blood Date: 2017-02-01 Impact factor: 22.113

5. Bcl-xL protein protects from C/EBP homologous protein (CHOP)-dependent apoptosis during plasma cell differentiation.

Authors: Brian T Gaudette; Neal N Iwakoshi; Lawrence H Boise
Journal: J Biol Chem Date: 2014-07-14 Impact factor: 5.157

6. Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma.

Authors: Esperanza M Algarín; Andrea Díaz-Tejedor; Pedro Mogollón; Susana Hernández-García; Luis A Corchete; Laura San-Segundo; Montserrat Martín-Sánchez; Lorena González-Méndez; Marie Schoumacher; Sebastien Banquet; Laurence Kraus-Berthier; Ioana Kloos; Alix Derreal; Ensar Halilovic; Heiko Maacke; Norma C Gutiérrez; María-Victoria Mateos; Teresa Paíno; Mercedes Garayoa; Enrique M Ocio
Journal: Haematologica Date: 2019-07-18 Impact factor: 9.941

7. Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma.

Authors: Katelyn G Ponder; Shannon M Matulis; Sadae Hitosugi; Vikas A Gupta; Cathy Sharp; Francis Burrows; Ajay K Nooka; Jonathan L Kaufman; Sagar Lonial; Lawrence H Boise
Journal: Cancer Biol Ther Date: 2016-07-02 Impact factor: 4.742

8. Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells.

Authors: Mohamed Rahmani; Jewel Nkwocha; Elisa Hawkins; Xinyan Pei; Rebecca E Parker; Maciej Kmieciak; Joel D Leverson; Deepak Sampath; Andrea Ferreira-Gonzalez; Steven Grant
Journal: Cancer Res Date: 2018-03-20 Impact factor: 12.701

9. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.

Authors: Mohamed Rahmani; Mandy Mayo Aust; Elisa Attkisson; David C Williams; Andrea Ferreira-Gonzalez; Steven Grant
Journal: Cancer Res Date: 2012-12-12 Impact factor: 12.701

Review 10. The Tao of myeloma.

Authors: Lawrence H Boise; Jonathan L Kaufman; Nizar J Bahlis; Sagar Lonial; Kelvin P Lee
Journal: Blood Date: 2014-09-18 Impact factor: 22.113